Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 96Triple Negative Breast Neoplasms 42Breast Neoplasms, Male 18Inflammatory Breast Neoplasms 11Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 6Lung Neoplasms 5Carcinoma, Ovarian Epithelial 5Stomach Neoplasms 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Esophageal Neoplasms 4Endometrial Neoplasms 4Anatomic Stage I Breast Cancer AJCC v8 4Sarcoma 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Testicular Neoplasms 2Small Cell Lung Carcinoma 2Salivary Gland Neoplasms 2Neoplasms, Unknown Primary 2Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Breast Carcinoma In Situ 2Anatomic Stage II Breast Cancer AJCC v8 2Uterine Cervical Neoplasms 1Thrombocytosis 1

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Breast Carcinoma × Taxes × Breast × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡